The Interior Ministry attributed the drop in applications to stricter migration policies, but other factors also played a ...

Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to treat the rare disease, and has now launched a digital companion to help patients track their ...